NCT00450580 - HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults | Biotech Hunter

Enrollment

212

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Infection, Human Immunodeficiency Virus IHIV-1 Infection

Interventions

DRUG

fosamprenavir/ritonavir

Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent

Trial Locations (69)

1090

GSK Investigational Site, Brussels

2000

GSK Investigational Site, Antwerp

8400

GSK Investigational Site, Barcelona

9000

GSK Investigational Site, Ghent

9007

GSK Investigational Site, Sankt Gallen

15006

GSK Investigational Site, A Coruña

15706

GSK Investigational Site, Santiago de Compostela

20127

GSK Investigational Site, Milan

20142

GSK Investigational Site, Milan

20146

GSK Investigational Site, Hamburg

20246

GSK Investigational Site, Hamburg

21052

GSK Investigational Site, Busto Arsizio (VA)

25030

GSK Investigational Site, Besançon

25125

GSK Investigational Site, Brescia

28029

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

GSK Investigational Site, Marid

28041

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

30159

GSK Investigational Site, Hanover

30625

GSK Investigational Site, Hanover

33000

GSK Investigational Site, Bordeaux

41013

GSK Investigational Site, Seville

44093

GSK Investigational Site, Nantes

44137

GSK Investigational Site, Dortmund

45100

GSK Investigational Site, Orléans

46015

GSK Investigational Site, Valencia

49090

GSK Investigational Site, Osnabrück

50937

GSK Investigational Site, Cologne

58100

GSK Investigational Site, Grosseto

59208

GSK Investigational Site, Tourcoing

60311

GSK Investigational Site, Frankfurt am Main

60590

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

67000

GSK Investigational Site, Strasbourg

69437

GSK Investigational Site, Lyon

70197

GSK Investigational Site, Stuttgart

75010

GSK Investigational Site, Paris

75018

GSK Investigational Site, Paris

75475

GSK Investigational Site, Paris

75651

GSK Investigational Site, Paris

79098

GSK Investigational Site, Freiburg im Breisgau

79106

GSK Investigational Site, Freiburg im Breisgau

80801

GSK Investigational Site, Munich

85025

GSK Investigational Site, La Roche-sur-Yon

88100

GSK Investigational Site, Catanzaro

90762

GSK Investigational Site, Fürth

92140

GSK Investigational Site, Clamart

92151

GSK Investigational Site, Suresnes

92300

GSK Investigational Site, Levallois-Perret

93205

GSK Investigational Site, Saint-Denis

196645

GSK Investigational Site, Saint Petersburg

400040

GSK Investigational Site, Volgograd

700116

GSK Investigational Site, Iași

900709

GSK Investigational Site, Constanța

06202

GSK Investigational Site, Nice

00161

GSK Investigational Site, Rome

00185

GSK Investigational Site, Rome

021105

GSK Investigational Site, Bucharest

030303

GSK Investigational Site, Bucharest

08025

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

03202

GSK Investigational Site, Elche (Alicante)

08034

GSK Investigational Site, Mataró

NW3 2QG

GSK Investigational Site, London

SE1 7EH

GSK Investigational Site, London

SW10 9TH

GSK Investigational Site, London